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Background
The binding of two biological targets with a single IgG-
based molecule is thought to be beneficial for clinical
efficacy. However the technological challenges for the
development of a bispecific platform are numerous.
While correct pairing of heterologous heavy and light
chains (Hc and Lc) can be achieved by engineering
native IgG scaffolds, crucial properties such as thermo-
stability, effector function and low immunogenicity
should be maintained [1]. The molecule has to be
expressed at industrially relevant levels with a minimum
fraction of contaminants and a scalable purification
approach is needed to isolate the product from poten-
tially complex mixtures. This article introduces a novel
bispecific platform based on the proprietary BEAT® tech-
nology (Bispecific Engagement by Antibodies based on
the T cell receptor) developed by Glenmark.
Materials and methods
Stable cell lines were generated by co-transfection of
three proprietary expression vectors pGLEX41_GA/GB
coding for the Hc, Lc and Fc-scFv under optimized stoi-
chiometric conditions in CHO-S cells. Cell lines were
selected according to expression and heterodimerization
during small scale fed-batch cultures performed in Tube-
Spin bioreactors (TPP, Trasadingen, Switzerland). For
high throughput (HT) screening, the fraction of BEAT®
molecule was evaluated using the Caliper LabChip GXII
Protein Assay (PerkinElmer, Waltham, Ma, USA). Titers
were measured by HPLC-PA after 14 days of culture.
The fraction of heterodimer in CHO supernatants was
measured by CE-CGE on Protein A (ProtA) purified
supernatants harvested on day 14. The actual BEAT®
titer was obtained by multiplying the concentration mea-
sured by HPLC-PA by the fraction of heterodimer mea-
sured by CE-CGE in ProtA purified supernatants. The
BEAT® was produced in 3 L STR bioreactors (Mobius
CellReady Bioreactor, Millipore) in fed-batch. Superna-
tants were typically harvested on day 14 by centrifugation
and dead-end filtration. A single Protein A step was per-
formed for purification, where two isocratic steps allowed
the selective elution of the bispecific product. The ther-
mostability of the BEAT® molecule was measured by
differential scanning calorimetry (DSC) in PBS.
Results
The BEAT® bispecific molecule consists of three chains: a
heavy chain (Hc), a light chain (Lc) and a Fc-scFv (see
Figure 1 A). The molecule has a fully functional Fc and
engages two biological targets by a Fab arm on one side
and by a scFv on the other. Heterodimerization is achieved
by a proprietary CH3 interface, mimicking the natural
association of the T-cell surface receptors a and b
between the two CH3 domains of IgG. Lc mispairing is
avoided by the replacement of one Fab arm of the bispeci-
fic IgG by a scFv. In addition, the Protein A binding site in
the Hc of the molecule is abrogated to facilitate the isola-
tion of the BEAT®-antibody by affinity chromatography
(discussed in the following). The DSC analysis of the
BEAT® indicated a good thermostability within the range
of naturally occurring antibodies. The BEAT® molecule is
expressed in CHO cells. Figure 1 A shows a typical secre-
tion profile obtained by Caliper Protein Analysis of a non-
purified CHO supernatant after 14 days in fed-batch
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culture. It can be seen that the asymmetry of the BEAT®
format allows an easy characterization of the secretion
profile of generated clones using HT analytics solely based
on molecular weight. The example illustrates that a very
low level of monospecific IgG is secreted and that the
main secreted species is the BEAT® molecule, the main
monospecific contaminant being the scFv-Fc homodimer.
Figure 1 B shows the distribution of the heterodimeriza-
tion level of the CHO clones screened during cell line
development. The median of the distribution is approx.
80 % indicating that half of the generated clones secreted
> 80 % of heterodimer. The expression level of the best 10
clones selected in small scale fed-batches after cell line
development can be seen in Figure 1 C. Clones secreting
1-2 g/L of BEAT®could be obtained under non-optimized
fed-batch conditions. Stability studies demonstrated that
selected CHO clones have a stable level of heterodimeriza-
tion over long term cultivation (75 population doubling
level (PDL), data not shown).
At 3 L bioreactor scale, titers of 3 g/L with 90 % of
secreted heterodimer could be obtained in fed-batch with
minimal feeding optimization. After harvest the molecule
is purified by Protein A (ProtA). For purification pur-
poses the BEAT® was designed with a missing ProtA
binding site on the Hc of the molecule. Consequently,
residual monospecific IgG contaminants (harboring
2 Hc) do not bind to the ProtA column and are thus
easily separated from the products of interest. In addi-
tion, the BEAT® molecule and the homodimeric Fc-scFv
contaminant exhibit a different affinity for Protein A as
the molecules harbor one and two binding sites for
ProtA, respectively. Thus, the BEAT® molecule can be
separated by ProtA via a two-step isocratic elution as illu-
strated in Figure 1 D. Applying this purification strategy
for harvested bioreactor material, a level of purity of 97 %
could be obtained post ProtA.
Conclusions
This work introduces a new bispecific IgG format called
the BEAT®. Glenmark’s BEAT® platform allows the gen-
eration of stable clones with volumetric productivity of
several g/L and a high heterodimerization level (> 90 %
secreted BEAT® in CHO supernatants). Generated clones
harbor stable product quality profiles, e.g. level of hetero-
dimerization, over at least 75 PDL. The developed purifi-
cation strategy allows a purity reaching 97 % post ProtA.
The BEAT® platform combines a unique CH3 interface
for heterodimerization, an efficient cell line selection
Figure 1 The BEAT®bispecific platform. In A: secretion profile of a BEAT® secreting CHO clone obtained by Caliper analysis of a non-purified
supernatant. B: distribution of the heterodimerization level of stable clones at cell line development level. C: BEAT® expression level of 10
selected stable clones. D: BEAT® purification strategy.
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strategy and an industrial relevant purification process for
the production of pure bispecific antibody at several g/L.
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